A review on cullin neddylation and strategies to identify its inhibitors for cancer therapy.
Cancer
Cullin-RING E3 ligase
Inhibitor
NEDD8
Neddylation
Journal
3 Biotech
ISSN: 2190-572X
Titre abrégé: 3 Biotech
Pays: Germany
ID NLM: 101565857
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
06
10
2021
accepted:
29
01
2022
entrez:
25
4
2022
pubmed:
26
4
2022
medline:
26
4
2022
Statut:
ppublish
Résumé
The cullin-RING E3 ligases (CRLs) are the biggest components of the E3 ubiquitin ligase protein family, and they represent an essential role in various diseases that occur because of abnormal activation, particularly in tumors development. Regulation of CRLs needs neddylation, a post-translational modification involving an enzymatic cascade that transfers small, ubiquitin-like NEDD8 protein to CRLs. Many previous studies have confirmed neddylation as an enticing target for anticancer drug discoveries, and few recent studies have also found a significant increase in advancement in protein neddylation, including preclinical and clinical target validation to discover the neddylation inhibitor compound. In the present review, we first presented briefly the essence of CRLs' neddylation and its control, systematic analysis of CRLs, followed by the description of a few recorded chemical inhibitors of CRLs neddylation enzymes with recent examples of preclinical and clinical targets. We have also listed various structure-based pointing of protein-protein dealings in the CRLs' neddylation reaction, and last, the methods available to discover new inhibitors of neddylation are elaborated. This review will offer a concentrated, up-to-date, and detailed description of the discovery of neddylation inhibitors.
Identifiants
pubmed: 35463041
doi: 10.1007/s13205-022-03162-x
pii: 3162
pmc: PMC8964847
doi:
Types de publication
Journal Article
Langues
eng
Pagination
103Informations de copyright
© King Abdulaziz City for Science and Technology 2022.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare no conflict of interest could be perceived as prejudicial to the impartiality of the reported research.
Références
Future Med Chem. 2021 Jul;13(14):1203-1226
pubmed: 34015962
Pharmacol Rev. 2021 Jan;73(1):1-58
pubmed: 33177128
J Med Chem. 2018 Apr 12;61(7):2680-2693
pubmed: 29547696
Oncogene. 2019 Jul;38(29):5792-5804
pubmed: 31243299
Front Cell Dev Biol. 2021 Apr 08;9:653882
pubmed: 33898451
Exp Mol Med. 2020 Oct;52(10):1637-1651
pubmed: 33005013
Biochimie. 2012 Nov;94(11):2457-60
pubmed: 22709868
Leukemia. 2021 Feb;35(2):360-376
pubmed: 33149266
Curr Oncol Rep. 2020 Jun 8;22(7):66
pubmed: 32514632
Semin Cancer Biol. 2021 Nov;76:38-44
pubmed: 34416372
Biomolecules. 2020 Sep 13;10(9):
pubmed: 32933137
Cancers (Basel). 2020 Sep 14;12(9):
pubmed: 32937954
Semin Cancer Biol. 2020 Dec;67(Pt 2):80-91
pubmed: 32165320
Cancers (Basel). 2021 Jun 20;13(12):
pubmed: 34203106
Circulation. 2011 May 17;123(19):2145-56
pubmed: 21576679
Mol Cell. 2009 May 14;34(4):451-60
pubmed: 19481525
Nat Protoc. 2013;8(7):1307-20
pubmed: 23764938
Eur J Med Chem. 2020 Dec 1;207:112764
pubmed: 32871340
Mol Cell Biol. 2004 Aug;24(16):7130-9
pubmed: 15282312
Nat Rev Mol Cell Biol. 2015 Jan;16(1):30-44
pubmed: 25531226
Front Oncol. 2020 Aug 21;10:1517
pubmed: 32983997
Nat Commun. 2021 Oct 12;12(1):5939
pubmed: 34642328
J Mol Cell Biol. 2019 Sep 19;11(9):725-735
pubmed: 30590706
Toxicol Appl Pharmacol. 2008 Mar 1;227(2):163-78
pubmed: 18063003
Nature. 2021 Feb;590(7847):671-676
pubmed: 33536622
Cells. 2020 Jun 03;9(6):
pubmed: 32503256
Antioxid Redox Signal. 2014 Dec 10;21(17):2383-400
pubmed: 24410571
Oncogene. 2021 Feb;40(7):1217-1230
pubmed: 33420360
Signal Transduct Target Ther. 2020 Aug 12;5(1):150
pubmed: 32788639
J Hematol Oncol. 2020 Jul 11;13(1):90
pubmed: 32653017
Cancers (Basel). 2020 Apr 07;12(4):
pubmed: 32272746
Bioengineered. 2021 Dec;12(1):5348-5360
pubmed: 34415831
Cancer Cell. 2011 Feb 15;19(2):168-76
pubmed: 21316600
Eur J Med Chem. 2018 Apr 25;150:9-29
pubmed: 29505935
Cancers (Basel). 2021 Sep 29;13(19):
pubmed: 34638383
Mech Ageing Dev. 2021 Apr;195:111466
pubmed: 33727156
Cell. 2008 Aug 22;134(4):668-78
pubmed: 18724939
Neoplasia. 2020 Apr;22(4):179-191
pubmed: 32145688
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
Acta Pharm Sin B. 2021 Nov;11(11):3567-3584
pubmed: 34900537
Chem Sci. 2015 Sep 1;6(9):5235-5245
pubmed: 28717502
Pharmaceutics. 2020 Jun 29;12(7):
pubmed: 32610448
Int J Mol Sci. 2021 Nov 25;22(23):
pubmed: 34884555
Curr Opin Struct Biol. 2021 Apr;67:110-119
pubmed: 33271439
Front Oncol. 2021 Jun 14;11:681377
pubmed: 34195082
Protein Sci. 2021 Nov;30(11):2338-2345
pubmed: 34459035
Eur J Med Chem. 2020 Jun 1;195:112275
pubmed: 32283298
Genes Cancer. 2010 Jul;1(7):708-16
pubmed: 21779466
Cell Death Differ. 2021 Feb;28(2):591-605
pubmed: 33432113
Front Physiol. 2020 Dec 17;11:612927
pubmed: 33391028
FEBS J. 2021 Jun;288(11):3351-3374
pubmed: 33021036
Cancers (Basel). 2020 Jun 16;12(6):
pubmed: 32560247
Nature. 2009 Apr 9;458(7239):732-6
pubmed: 19360080
Structure. 2017 Jul 5;25(7):1120-1129.e3
pubmed: 28578874
Front Cell Dev Biol. 2021 Apr 30;9:667435
pubmed: 33996822
Nat Rev Mol Cell Biol. 2009 May;10(5):319-31
pubmed: 19352404
Cell Chem Biol. 2021 Jul 15;28(7):1000-1013
pubmed: 33891901
Eur J Med Chem. 2020 Jan 1;185:111848
pubmed: 31732254
Sci Rep. 2020 Nov 2;10(1):18850
pubmed: 33139812
Front Oncol. 2020 Nov 25;10:574011
pubmed: 33324551
Prog Med Chem. 2021;60:67-190
pubmed: 34147206
Cancer Cell. 2021 Apr 12;39(4):466-479
pubmed: 33450197
Biochimie. 2014 Jul;102:211-5
pubmed: 24657219
Cancer Sci. 2019 Dec;110(12):3802-3810
pubmed: 31583781
ACS Med Chem Lett. 2020 Mar 18;11(4):575-581
pubmed: 32292566
Biomedicines. 2021 Jan 27;9(2):
pubmed: 33513829
Cell Div. 2016 Mar 09;11:1
pubmed: 27030794
J Med Chem. 2022 Jan 13;65(1):84-99
pubmed: 34928151
Cell Death Discov. 2020 Jan 20;6:2
pubmed: 32123578
ACS Appl Bio Mater. 2021 Jan 18;4(1):24-46
pubmed: 35014275
Blood. 2018 Mar 29;131(13):1415-1424
pubmed: 29348128
Blood. 2010 Sep 2;116(9):1515-23
pubmed: 20525923
Expert Opin Ther Targets. 2011 Mar;15(3):253-64
pubmed: 21219242
Mol Cell Proteomics. 2021;20:100016
pubmed: 33556866
Semin Cancer Biol. 2020 Dec;67(Pt 2):16-33
pubmed: 32014608
Leukemia. 2021 Jul;35(7):2119-2124
pubmed: 33483617
Oncogene. 2020 Mar;39(11):2358-2376
pubmed: 31911619
J Cell Sci. 2016 Apr 1;129(7):1441-54
pubmed: 26906416
Sci Rep. 2020 Aug 18;10(1):13942
pubmed: 32811853
Mol Cancer. 2020 Oct 1;19(1):146
pubmed: 33004065
Mol Cancer Ther. 2019 Jul;18(7):1205-1216
pubmed: 31092565
Arch Pharm Res. 2020 Nov;43(11):1144-1161
pubmed: 33165832
Cell Death Dis. 2021 Jul 26;12(8):736
pubmed: 34312366
Curr Opin Struct Biol. 2021 Apr;67:101-109
pubmed: 33160249
Nat Med. 2018 Feb;24(2):186-193
pubmed: 29334375
Nature. 2020 Feb;578(7795):461-466
pubmed: 32051583
Am J Cancer Res. 2020 Mar 01;10(3):953-964
pubmed: 32266102
Biotechnol Appl Biochem. 2022 Feb;69(1):330-341
pubmed: 33469954
Cell Biosci. 2021 Mar 17;11(1):55
pubmed: 33731189
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):27980-27988
pubmed: 33093207
Angew Chem Int Ed Engl. 2014 Feb 24;53(9):2312-30
pubmed: 24459094
Evid Based Complement Alternat Med. 2021 Jul 9;2021:5631942
pubmed: 34306145
FEBS J. 2021 Jul;288(13):3884-3912
pubmed: 33025631
Blood Cancer Discov. 2020 Nov 24;2(1):19-31
pubmed: 34661151
J Mol Cell Biol. 2022 Jan 21;13(11):774-785
pubmed: 34289043
Signal Transduct Target Ther. 2020 Jun 10;5(1):90
pubmed: 32532965
Nat Rev Drug Discov. 2014 Dec;13(12):889-903
pubmed: 25394868
Nat Struct Mol Biol. 2016 Aug;23(8):730-7
pubmed: 27348078
Int J Mol Sci. 2021 Jul 15;22(14):
pubmed: 34299191
J Biol Chem. 2011 Nov 25;286(47):40867-77
pubmed: 21969368
Int J Mol Sci. 2021 Jun 18;22(12):
pubmed: 34207315
Open Biol. 2014 Feb 12;4:130217
pubmed: 24522884
ACS Chem Biol. 2016 Jul 15;11(7):1901-7
pubmed: 27135934
Mass Spectrom Rev. 2011 Mar-Apr;30(2):221-35
pubmed: 21337598
Int J Mol Sci. 2021 Feb 09;22(4):
pubmed: 33572115
Oncotarget. 2021 Oct 12;12(21):2227-2230
pubmed: 34676055
Front Cell Dev Biol. 2020 Aug 31;8:843
pubmed: 32984335
J Chem Inf Model. 2014 Jun 23;54(6):1785-97
pubmed: 24857708